RxDoctor Payments Data

Jan Michael Arceo

Psychiatric/Mental Health · Las Vegas, NVNPI 1750857728

Payments from drug & device makers

$2,252in general payments, 2019–2025

Across 120 payments — averaging $18.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$812
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$434
  • Sunovion Pharmaceuticals Inc.$151
  • Corium, LLC$127
  • Alkermes, Inc.$109
  • Almatica Pharma LLC$97
  • plus $522 from 11 others

What the payments were for

  • Food & beverage$2,20598%
  • Education$472%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,252 in reported general payments places this provider in the 75th percentile of 362 psychiatric/mental health providers in Nevada.

See all psychiatric/mental health providers in Nevada

Medicare billing

Part B allowed, 2024
$221,364
Medicare patients
128
Services billed
3,957

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl87$125,691
ClozarilClozapine25$21,301
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl160$20,212
MovantikNaloxegol Oxalate19$17,445
Aripiprazole176$14,344
Quetiapine Fumarate ErQuetiapine Fumarate67$10,685
ZubsolvBuprenorphine Hcl/Naloxone Hcl22$8,981
Lurasidone Hcl36$8,089
TrintellixVortioxetine Hydrobromide15$6,584
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine90$5,713
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine208$5,307
VyvanseLisdexamfetamine Dimesylate11$4,542
Duloxetine Hcl213$4,018
Alprazolam311$2,924
Lisdexamfetamine Dimesylate12$2,636

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$812$125,69187 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse$17$11,12626 claims
Almatica Pharma LLCSertraline Hcl$97$793134 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 362 psychiatric/mental health providers in Nevada.

Other psychiatric/mental health in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →